Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
1 finding from 1 review
Safety Any serious adverse event · adults with advanced disease for muscle weakness
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
SAEs · participants with obesity
The review found no eligible studies for this question.
1 finding from 1 review
Overall serious adverse events · people who smoke
1 finding from 1 review
Overall serious adverse events · people who smoke
Combination showed no clear difference in overall serious adverse events compared with single‐form nicotine replacement therapy (low certainty).
1 finding from 1 review
Overall serious adverse events · people who smoke
1 finding from 1 review
Intervention not reported
Overall serious adverse events · people who smoke
1 finding from 1 review
Overall serious adverse events · people who smoke
Preloading nicotine replacement therapy (NRT) showed no clear difference in overall serious adverse events compared with standard‐use NRT (low certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review